| Prev Close | 104.70 |
| Open | 105.25 |
| Day Low/High | 104.30 / 105.49 |
| 52 Wk Low/High | 86.97 / 119.05 |
| Volume | 173.70K |
| Avg Volume | 388.40K |
| Exchange | NYSE |
| Shares Outstanding | 47.95M |
| Market Cap | 5.04B |
| EPS | 2.60 |
| P/E Ratio | 41.42 |
| Div & Yield | N.A. (N.A) |
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has refinanced its existing $1.
Charles River Laboratories International, Inc. (NYSE: CRL) recently announced several key expansions to its global Biologics Testing Solutions infrastructure to support the characterization, development, and release of...
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Raymond James 39 th Annual Institutional Investors Conference in Orlando, Florida, on Tuesday, March 6 th, at 3:25 p.
Charles River Laboratories International, Inc. (NYSE: CRL) recently announced the launch of its new online Tumor Model Compendium web interface.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: OMC, WMS Downgrades: ALSK, ATV, BP, CARB, CMP, CRL, DAN, FRT, SNY, VNO, WU, ZIXI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Charles River Laboratories International, Inc. (NYSE: CRL) today announced two new executive management appointments.
Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth-quarter and full-year 2017 and provided guidance for 2018.
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive agreement to acquire MPI Research for approximately $800 million in cash, subject to customary closing...
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca's (NYSE: AZN) high-throughput screening (HTS) and compound management...
Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2017 financial results and provide 2018 guidance on Tuesday, February 13 th, before the market opens.
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Jean-Paul Mangeolle, former President of AB SCIEX, to its Board of Directors.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has acquired KWS BioTest, a leading contract research organization (CRO) specializing in in vitro and in vivo discovery testing services...
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 36 th Annual J.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its CRISPR/Cas9 service offering with the addition of a license from ERS Genomics Limited.
Charles River Laboratories International, Inc. (NYSE: CRL) and ENYO Pharma SA today announced the results of a successful collaboration.
Jim Cramer spotlights Alteryx, Charles River Labs, Mallinckrodt, and GoPro.
Don't take your cues solely from the action, Jim Cramer says. Big money managers get things wrong all the time, and many stocks are behaving irrationally.
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2017.
